Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
bioAffinity Technologies, Inc. - Common Stock
(NQ:
BIAF
)
1.870
+0.010 (+0.54%)
Streaming Delayed Price
Updated: 11:26 AM EDT, Jun 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about bioAffinity Technologies, Inc. - Common Stock
< Previous
1
2
3
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Today 9:06 EDT
Via
Benzinga
bioAffinity Technologies Presents Research Findings at CYTO 2023
May 22, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports First Quarter 2023 Financial Results
May 15, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer
May 01, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium
April 25, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies to Ring Nasdaq Closing Bell Today
April 05, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
March 31, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer
March 28, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023
March 24, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 14, 2023
Via
Benzinga
bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications
February 13, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
Dow Rises 80 Points; Altamira Therapeutics Shares Plunge
January 24, 2023
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 80 points on Tuesday. The Dow traded up 0.24% to 33,710.06 while the NASDAQ fell 0.21% to 11,340.24. The S&P 500...
Via
Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 24, 2023
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 24, 2023
Via
Benzinga
Dow Edges Higher; Crude Oil Down 1%
January 24, 2023
U.S. stocks traded mostly flat midway through trading, with the Dow Jones trading slightly higher on Tuesday. The Dow traded up 0.03% to 33,638.42 while the NASDAQ fell 0.07% to 11,356.65. The S&P 500...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 24, 2023
Via
Benzinga
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
January 24, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
January 04, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 28, 2022
Via
Benzinga
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
December 15, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
December 09, 2022
Via
Benzinga
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
December 01, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 30, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 21, 2022
Via
Benzinga
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
November 10, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
November 08, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia
October 25, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 21, 2022
Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 33.1% to $0.2 during Friday's pre-market session. The company's market cap stands at $10.4 million.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
